Biotech | August 17, 2021
Indian pharma’s vaccine opportunity at US $ 10-11 billion
Domestic market and developing countries will need doses of Indian vaccines
Domestic market and developing countries will need doses of Indian vaccines
_256_384.jpg)
The antiviral technology involves the presence of active positive charges on the fabric, as binding sites for viruses and on contact with the fabric, virus cells that are negatively charged are neutralised, leading to the rapid destruction of their glycoprotein layers and the release of non-infectious ribonucleic acid (RNA)
A treatment to prevent extreme symptoms and cut hospitalisation
A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
If approved it will bring a second source of MMR vaccine to the US market
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Formulation business grew by 15 per cent in the quarter
Deal signed with AOP Orphan for US commercial rights
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Subscribe To Our Newsletter & Stay Updated
